Fulcrum Therapeutics Inc. Overview
Fulcrum Therapeutics, Inc., a prominent player in the health care sector, is headquartered in Cambridge, United States. The company is renowned for its innovative approach to pharmaceutical development, focusing on gene regulation to address various diseases. Fulcrum Therapeutics is dedicated to revolutionizing the treatment landscape by developing drugs that target gene regulation, a niche yet critical area in modern medicine.
Financial Snapshot
As of July 6, 2025, Fulcrum Therapeutics’ stock closed at $7.02 on the Nasdaq exchange. The company’s market capitalization stands at approximately $383,253,110 USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $10.13 on August 14, 2024, and a 52-week low of $2.315 on April 6, 2025.
Market Focus and Operations
Fulcrum Therapeutics serves the Massachusetts healthcare sector exclusively, leveraging its strategic location in Cambridge to foster innovation and collaboration within the region. The company’s commitment to developing groundbreaking pharmaceutical products is evident in its specialized focus on gene regulation, aiming to transform therapeutic approaches for various diseases.
Further Information
For more detailed information about Fulcrum Therapeutics’ products and services, interested parties can visit their official website at www.fulcrumtx.com . The company continues to be a key player in the health care sector, with its shares actively traded on the Nasdaq stock exchange.